UCLA Scientists Engineer Cord Blood Into Off-the-Shelf Cancer-Fighting T Cells

Researchers at the University of California, Los Angeles have developed a scalable method to transform donated umbilical cord blood stem cells into ready-made, cancer-fighting T cells capable of targeting solid tumors. Published in the journal Cell Reports Medicine, the preclinical study demonstrates that these engineered cells, named AlloESO-T, can control tumor growth and prolong survival in animal models without triggering a common, life-threatening transplant complication.

The development addresses two of the most persistent bottlenecks in modern cancer immunotherapy: the exorbitant cost of personalized treatments and the risk of graft-versus-host disease associated with donor-derived therapies. By engineering cells at an embryonic stem-cell stage rather than modifying mature donor cells, the UCLA team has established a blueprint for mass-producing off-the-shelf treatments that could eventually be frozen, stored, and distributed to patients on demand.

Current T-cell receptor (TCR) therapies, which genetically reprogram a patient's own immune cells to recognize cancer, are highly personalized. While effective, this bespoke manufacturing process is slow, often taking weeks to complete, and can cost hundreds of thousands of dollars per patient. Attempts to use healthy donor T cells as a pre-manufactured alternative have historically run into a severe immunological barrier known as graft-versus-host disease, where the transplanted cells mistakenly attack the recipient's healthy tissues.

The UCLA research team bypassed this obstacle by starting with undifferentiated hematopoietic stem cells extracted from donated cord blood rather than mature T cells. "Stem cells are undifferentiated, they're not yet mature T cells with a fixed receptor already in place," explained co-first author Yichen Zhu, a graduate student in the UCLA Broad Stem Cell Research Center Training Program. "When we differentiate our engineered stem cells into T cells, essentially all of the resulting cells carry the same receptor and go after the same tumor target."

Because these stem cells develop their receptors under controlled laboratory conditions, they do not acquire the diverse, random array of natural receptors that typically trigger graft-versus-host disease. This eliminates the need for complex, multi-step gene editing to silence native receptors, a process required when modifying mature donor T cells.

Solid tumors present a unique challenge for immunotherapies due to their cellular diversity. Over time, cancer cells can stop displaying the specific molecular marker a therapy is designed to find, a survival mechanism known as antigen escape. To prevent this, the UCLA scientists engineered the AlloESO-T cells with a dual-detection system.

The primary targeting mechanism uses an engineered TCR designed to recognize NY-ESO-1, a protein found inside many solid tumors that presents fragments on the cell surface. To supplement this, the researchers preserved the cells' natural killer receptors, which detect stress signals displayed by cancer cells. "Solid tumors are very diverse," Zhu noted. "Some tumor cells lose or hide the antigen a therapy is designed to find, what we call antigen escape. When that happens, a therapy built around a single target loses its grip. Our stem cell-derived cells still have a second mechanism to kill those tumor cells."

In laboratory tests, this secondary pathway allowed the engineered T cells to destroy human melanoma, ovarian, and prostate cancer cells that had managed to evade the primary NY-ESO-1 targeting mechanism. This dual-targeting capability could potentially close off one of the primary escape routes that limits therapies aimed at only a single cancer marker.

When evaluated in mouse models of ovarian cancer and melanoma, a single infusion of AlloESO-T cells achieved sustained tumor control and significantly extended survival. In contrast, mice treated with conventional therapies derived from mature donor T cells showed only temporary tumor control and rapidly developed severe graft-versus-host disease.

The study also revealed stark differences in how the cells behaved inside the living organisms. Following administration, the AlloESO-T cells expanded in number by approximately 100-fold, successfully migrated into the tumors, and remained active for several weeks. Crucially, they avoided healthy organs, whereas the conventionally engineered donor T cells accumulated in the liver and lungs, causing toxic side effects.

"This platform brings us closer to a future where the product is already made, frozen and ready to go as soon as the patient needs," said co-senior author Lili Yang, a professor of microbiology, immunology and molecular genetics and a member of the UCLA Broad Stem Cell Research Center.

Beyond safety and efficacy, the manufacturing potential of the cord blood platform represents a significant shift in scalability. Because hematopoietic stem cells possess a high capacity for self-renewal and differentiation, a single donated cord blood sample can yield an immense volume of therapeutic cells.

"From a small number of cord blood stem cells, we can generate trillions of therapeutic cells, enough for thousands of doses, within about six weeks," said co-senior author Yanruide Li, a postdoctoral scholar in the Yang lab. "At an estimated $5,000 per dose, this approach would be far more accessible than today's therapies."

The researchers emphasize that the platform is highly adaptable. "We're not just presenting one therapy for one target. We want to share the platform itself," Li said. "As long as a receptor for a given cancer antigen has been validated, we can build it into this system and generate T cells specific to that target."

Despite the promising results in laboratory and animal models, the AlloESO-T platform remains in the preclinical phase. The therapy has not yet been tested in human clinical trials, and it has not received safety or efficacy approval from the U.S. Food and Drug Administration.

To transition the technology toward human testing, the UCLA researchers plan to leverage their existing manufacturing partnership with the UCLA Health Center for Advanced Biotherapies. This facility is already producing clinical-grade cells for the laboratory's separate CAR-NKT immunotherapy program, providing an established regulatory and production pipeline that could accelerate the timeline for launching first-in-human clinical trials of AlloESO-T.